Wednesday, July 3, 2019

Update - July 3rd, 2019

Webinars -

Regulatory -

Partnerships -

Lilly taps Avidity's antibody-oligonucleotide conjugate tech in $35M deal
- In an extension of ADC technology, Lilly is looking use Avidity's AOC tech to bring ADC concepts beyond oncology and into RNA specific diseases

SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
Yahoo News
- SpringWorks is looking to collaborate with GSK and their belantamab mafodotin BCMA targeting ADC in combination with their gamma secretase inhibitor

Manuscripts -

Reports -

Clinical Results -

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
Yahoo News
- ADC T continues their stellar run with clinical results.  Pay attention to these guys

Analyst offers Amgen a boost for its rival anti-BCMA BiTE, blemishing GSK as well as CAR-T rivals Celgene and bluebird
Endpoints News
- Lookout GSK, Amgen is looking at a small molecule approach to come after BCMA.  And incredibly, their first clinical indication is showing 5 out of 22 patients had a stringent complete response which beats out all of the other BCMA targeting therapies in the clinic right now

Industry - 

Bluebird Bio delays Zynteglo launch as manufacturing trips up another gene therapy
- To all of us ADC researchers, there is a tendency to see gene therapy as the cool kid in class.  But like in the early days of ADC development, the concept is much simpler than the execution.  And gene therapy will have some serious questions to answer as it develops further

Piramal Invests $10 million in Riverview Expansion
Contract Pharma
- Piramal is expanding their HPAPI production suite in the Riverview, Michigan facility to add two kilo labs as well as a new QC suite

Immunomedics: Our take on this battleground stock
Seeking Alpha
- A nice overview of Immunomedics from a stock investor perspective.  Conclusion : future outlook is risky at best

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares
- Zymeworks continues to build the war chest.  With a nice combination of in-house assets and out-licensing opportunities, these guys are looking to become big players in the ADC world

WuXi invests in ADCs again to prep for commercial products
Bioprocess International
- WuXi continues their steady march towards ADC world domination by adding fill/finish onto their $20M mAb and conjugation facility.  Plans are to complete construction by the end of the year.  But will they be ready from a regulatory standpoint

Thats it for today. There are always more coming down the pike. Is there something I missed? Contact me. [email protected]
- - - [Main]

No comments:

Post a Comment